His main research concerns Breast cancer, Internal medicine, Oncology, Genome-wide association study and Cancer. His Breast cancer study combines topics from a wide range of disciplines, such as Single-nucleotide polymorphism, Gynecology and Bioinformatics. His Internal medicine research incorporates elements of Germline mutation and Pathology.
His Oncology study integrates concerns from other disciplines, such as Odds ratio, Case-control study, Bevacizumab, Prospective cohort study and Triple-negative breast cancer. His Genome-wide association study study incorporates themes from Estrogen receptor and Genetic predisposition. His studies in Cancer integrate themes in fields like Chromatin, microRNA and Estrogen.
Peter A. Fasching spends much of his time researching Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy. Peter A. Fasching combines subjects such as Genome-wide association study and Single-nucleotide polymorphism with his study of Breast cancer. To a larger extent, Peter A. Fasching studies Genetics with the aim of understanding Genome-wide association study.
His study in Odds ratio, Hazard ratio, Trastuzumab, Epirubicin and Clinical trial falls under the purview of Internal medicine. His Oncology research is multidisciplinary, incorporating elements of Circulating tumor cell, Prospective cohort study, Pathology, Docetaxel and Triple-negative breast cancer. The various areas that he examines in his Metastatic breast cancer study include Progression-free survival and Clinical significance.
His primary areas of investigation include Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer. His study in the fields of Chemotherapy, Trastuzumab and Randomized controlled trial under the domain of Internal medicine overlaps with other disciplines such as In patient. His Breast cancer research integrates issues from Odds ratio and Clinical trial.
His study in Oncology is interdisciplinary in nature, drawing from both Fulvestrant, Hazard ratio, Pertuzumab, Epirubicin and Triple-negative breast cancer. The concepts of his Cancer study are interwoven with issues in Tolerability and Family medicine. His Metastatic breast cancer research is multidisciplinary, incorporating perspectives in Interim analysis, Lapatinib and Clinical significance.
Peter A. Fasching mainly focuses on Breast cancer, Internal medicine, Oncology, Triple-negative breast cancer and Cancer. The Breast cancer study combines topics in areas such as Odds ratio and Epidemiology. His is doing research in Randomized controlled trial, Chemotherapy, Clinical trial, Tissue microarray and Adverse effect, both of which are found in Internal medicine.
His studies deal with areas such as Chemotherapy regimen and Hazard ratio as well as Randomized controlled trial. His Chemotherapy research includes themes of Adjuvant and Abemaciclib. His Oncology study combines topics in areas such as Epirubicin, Fulvestrant and Immunotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta.
The Lancet (2014)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa.
Journal of Clinical Oncology (2012)
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
Kyriaki Michailidou;Per Hall;Anna Gonzalez-Neira;Maya Ghoussaini.
Nature Genetics (2013)
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
Ganna Chornokur;Hui-Yi Lin;Jonathan P. Tyrer;Kate Lawrenson.
PLOS ONE (2015)
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
Celeste Leigh Pearce;Claire Templeman;Mary Anne Rossing;Alice Lee.
Lancet Oncology (2012)
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
Xiaohong R. Yang;Jenny Chang-Claude;Ellen L. Goode;Fergus J. Couch.
Journal of the National Cancer Institute (2011)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat.
Lancet Oncology (2014)
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl.
The New England Journal of Medicine (2019)
RAD51B in Familial Breast Cancer
Liisa M. Pelttari;Sofia Khan;Mikko Vuorela;Johanna I. Kiiski.
PLOS ONE (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: